연구동향 분석

원저 : 진행성 대장암 환자에서 FOLFOX4 복합화학약물 치료의 실패 후 2차 요법으로 FOLFIRI 복합화학약물 치료의 효과와 안전성

김재현 ( Jae Hyun Kim ) 박선자 ( Seun Ja Park ) 박무인 ( Moo In Park ) 문원 ( Won Moon ) 김성은 ( Sung Eun Kim ) 구기환 ( Ki Hwan Ku ) 송성은 ( Sung Eun Song ) 김제훈 ( Je Hun Kim ) 2014년

논문상세정보
인용/피인용
' 원저 : 진행성 대장암 환자에서 FOLFOX4 복합화학약물 치료의 실패 후 2차 요법으로 FOLFIRI 복합화학약물 치료의 효과와 안전성' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • chemotherapy
  • colorectal cancer
  • folfox4protocol
  • iflprotocol
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
536 0

0.0%

' 원저 : 진행성 대장암 환자에서 FOLFOX4 복합화학약물 치료의 실패 후 2차 요법으로 FOLFIRI 복합화학약물 치료의 효과와 안전성' 의 참고문헌

  • 전이성 혹은 재발성 위선암에서 oxaliplatin, Leucovorin, Fluorouracil과 Irinotecan, Leucovorin, Fluorouracil 병합 요법의 효과에 대한 비교 연구
    강선형 대한소화기학회지 55 (1) : 26 ~ 32 [2010]
  • Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial
    Rothenberg ML J Clin Oncol 21 : 2059 ~ 2069 - [2003]
  • Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study
    Hochster HS J Clin Oncol 26 : 3523 ~ 3529 - [2008]
  • SEOM clinical guidelines for the treatment of advanced colorectal cancer 2013
    Casado-Saenz E Clin Transl Oncol 15 : 996 ~ 1003 - [2013]
  • Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer
    Goldberg RM Cancer Chemother Pharmacol 54 (1) : S57 ~ S64 - [2004]
  • Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
    Pitot HC J Clin Oncol 15 : 2910 ~ 2919 - [1997]
  • Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin
    Bao HY Cancer Chemother Pharmacol 67 : 147 ~ 152 - [2011]
  • NCCN clinical practice guidelines in oncology
  • Multicenter phase II study of modified FOLFIRI regimen in the advanced colorectal cancer patient refractory to fluoropyrimidine and oxaliplatin
    Zhang W Zhonghua Zhong Liu Za Zhi 28 : 788 ~ 790 - [2006]
  • Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
    전은경 Cancer Research and Treatment 43 (3) : 148 ~ 153 [2011]
  • Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont A J Clin Oncol 18 : 2938 ~ 2947 [2000]
  • Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group
    Saltz LB N Engl J Med 343 : 905 ~ 914 - [2000]
  • Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
    Conti JA J Clin Oncol 14 : 709 ~ 715 - [1996]
  • Irinotecan in the treatment of colorectal cancer: clinical overview
    Vanhoefer U J Clin Oncol 19 : 1501 ~ 1518 - [2001]
  • Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
    Douillard JY Lancet 355 : 1041 ~ 1047 - [2000]
  • Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
    Kawato Y Cancer Res 51 : 4187 ~ 4191 - [1991]
  • Gruppo Oncologico Dell'Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
    Colucci G J Clin Oncol 23 : 4866 ~ 4875 - [2005]
  • FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer : a randomized GERCOR study
    Tournigand C J Clin Oncol 22 : 229 ~ 237 - [2004]
  • FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials
    Beretta GD Med Oncol 30 : 486 ~ - [2013]
  • Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
    Vale CL Cancer Treat Rev 38 : 618 ~ 625 - [2012]
  • Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals
    Liu JY Anticancer Drugs 18 : 693 ~ 696 - [2007]
  • Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea
    Lee EK Clin Ther 34 : 1408 ~ 1419 - [2012]
  • Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010
    정규원 Cancer Research and Treatment 45 (1) : 1 ~ 14 [2013]
  • CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous- infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
    André T GERCOR. Eur J Cancer 35 : 1343 ~ 1347 [1999]
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz H N Engl J Med 350 : 2335 ~ 2342 [2004]
  • Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer : results of a randomized phase II trial
    Kabbinavar FF J Clin Oncol 23 : 3697 ~ 3705 - [2005]
  • A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients
    Mabro M Br J Cancer 94 : 1287 ~ 1292 [2006]